Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

News

Vator Securities advises Precise Biometrics on 83 MSEK Directed & Rights Issue

11 August 2022

Precise Biometrics AB is a global identification software provider, offering products with a range of application for identification in a convenient and secure way. Precise offers products with various applications that enable individuals to identify themselves by using biometrics.

Precise operates through two product areas: Digital Identity, which enable identification for physical access through biometrics (e.g., fingerprints, heart rate, facial and iris recognition) and Algo Software systems which is a leading embedded software for fingerprint recognition meeting various needs in smartphones, smart-lock doorhandles, and various applications in cars.

Read More

Vator Securities advises Rebelle on 315 MSEK M&A

25 July 2022

Rebelle operates the European online marketplace Rebelle.com for selling and buying luxury second hand fashion items and accessories.

Rebelle is offering products from the world’s most sought-after fashion brands, such as Louis Vuitton, Chanel, Gucci, Hermès and Prada while increasing customers awareness of sustainability and circularity within the fashion industry.

Read More

Vator Securities advises Movs Technology Group on 45 MSEK Private Placement

18 July 2022

Movs Technology Group is today the market leader in electric mopeds, and the leading dealer of electric bikes in Sweden. The company has developed several market-leading brands in Sweden: Baotian, Vässla, Drax, Niu and Lifebike.

The Mobility-as-a-Service service MOVS is a subscription service for long-term rental of bikes, as well as light electric vehicles such as electric bikes and electric mopeds.

Read More

Vator Securities acts as Joint Bookrunner on IRRAS 215 MSEK Rights Issue

4 July 2022

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients.

IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies.

Read More

Vator Securities advises ZignSec on 59 MSEK Rights Issue

25 May 2022

ZignSec AB (publ) is a RegTech company, providing an integrated end-to-end KYC, KYB compliance platform, facilitating seamless customer onboarding and monitoring, so clients can confidently expand operations internationally while remaining compliant.

Currently ZignSec has more than 500 customers spread across a range of industries where identification is essential, with the greatest concentration in financial services and other regulated activities.

Read More

Vator Securities advises Moberg Pharma on 121 MSEK Rights Issue

8 April 2022

Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis.

Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the Company’s goal is to receive its first market approval and launch MOB-015 in 2023.

Read More

Vator Securities advises ExpreS2ion Biotechnologies on 73 MSEK Rights Issue

6 April 2022

ExpreS2ion Biotech is a biotechnology company that develops vaccines based on complex proteins targeting infectious diseases and cancer. The company develops a pipeline of preventive and therapeutic vaccine products while generating revenue by outlicensing the company’s ExpreS2 platform.

The lead candidate targeting COVID-19 is outlicensed to Bavarian Nordic, with positive phase II data announced in February 2022 and phase III expected to be initiated during H1 2022. 

Read More

Vator Securities advises S2Medical on 21 MSEK Rights Issue

15 March 2022

S2Medical AB is a company founded in 2013 based in Linköping that develops and sells wound healing products with a focus on burns and chronic wounds.

The company aims to offer a holistic concept in wound healing with products in debridement (cleaning of wounds), granulation (construction of blood vessel-rich tissue) and re-epithelialization (outer tissue growth). 

Read More